Literature DB >> 26503963

Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.

Gabriela Franco Mourão1, Pedro Weslley Rosario2, Maria Regina Calsolari3.   

Abstract

This study evaluated the recurrence rate in patients with papillary thyroid carcinoma (PTC) who had low nonstimulated thyroglobulin (Tg), measured with a second-generation assay, after total thyroidectomy and who were not submitted to ablation with (131)I. The objective was to define whether low postoperative nonstimulated Tg can be used as a criterion to spare patients with PTC from therapy with (131)I. This was a prospective study including 222 patients with PTC (except for microcarcinoma restricted to the thyroid and tumor with extensive extrathyroid invasion (pT4), aggressive histology, extensive lymph node (LN) involvement, or known residual disease). After thyroidectomy, all patients had nonstimulated Tg<0.3 ng/ml, negative antithyroglobulin antibodies (TgAb) and neck ultrasonography (US) showing no anomalies. Because of this finding, the patients were not submitted to ablation with (131)I. The time of follow-up ranged from 15 to 102 months (median 62 months). Of the 222 patients, 217 (97.7%) continued to have nonstimulated Tg <0.3 ng/ml and negative US. Tg was undetectable in the last assessment in 185 of these patients and detectable in 32. Five patients (2.2%) exhibited an increase in Tg, and LN metastases were detected in 4 (structural recurrence). One patient progressed to an increase in Tg, but disease was not detected by the imaging methods (biochemical recurrence). The results obtained here suggest that patients with PTC who have low nonstimulated Tg (measured with a second-generation assay and in the absence of TgAb) and negative neck US after thyroidectomy do not require ablation with (131)I.
© 2016 Society for Endocrinology.

Entities:  

Keywords:  papillary thyroid carcinoma; postoperative nonstimulated thyroglobulin; radioiodine; recurrence

Mesh:

Substances:

Year:  2015        PMID: 26503963     DOI: 10.1530/ERC-15-0458

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  6 in total

1.  Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?

Authors:  Tian Tian; Rui Huang; Bin Liu
Journal:  Endocrine       Date:  2019-03-28       Impact factor: 3.633

2.  Risk of recurrence in patients with papillary thyroid carcinoma and minimal extrathyroidal extension not treated with radioiodine.

Authors:  P W Rosario; G Mourão; M R Calsolari
Journal:  J Endocrinol Invest       Date:  2018-10-23       Impact factor: 4.256

Review 3.  Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of Differentiated Thyroid Cancer.

Authors:  Einat Slonimsky; Mark Tulchinsky
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

4.  Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis.

Authors:  Shang Lin; Ya-Ru Wei; Hong-Xiang Yao
Journal:  Int J Gen Med       Date:  2021-12-14

5.  Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.

Authors:  Wasit Kanokwongnuwat; Noppadol Larbcharoensub; Chutintorn Sriphrapradang; Chaiyawat Suppasilp; Kanungnij Thamnirat; Chaninart Sakulpisuti; Arpakorn Kositwattanarerk; Chirawat Utamakul; Chanika Sritara; Wichana Chamroonrat
Journal:  Endocrine       Date:  2022-04-27       Impact factor: 3.925

Review 6.  The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer.

Authors:  Sha Li; Chutong Ren; Yi Gong; Fei Ye; Yulong Tang; Jiangyue Xu; Can Guo; Jiangsheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.